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Modulation of monocyte adherence to 
endothelial cells by endothelin-1 involvement 
of Src (p60 Src) and JAKl-like Idnases 
Lindsey J. Chisholm, MB, BS, Peter S. Dovgan, MD, Devendra K. Agrawal, PhD, 
Patrick E. McGregor, MD, and John D. Edwards, MD, Omaha, Neb. 
Purpose: The purpose of this study was to determine the transmembrane signaling pathway 
by which endothelin-1 (ET-1) enhances monocyte adherence to human umbilical vein 
endothelial cells (HUVECs) and to investigate the role of tyrosine kinases in this 
mechanism. 
Methods: Adherence of purified human blood monocytes to HUVEC monolayers was 
assessed with radiolabeled monocytes. Tyrosine kinase activation was examined by 
immunoprecipitation and Western blotting. 
Results: ET-1 potentiated monocyte adherence to HUVECs in a biphasic manner with 
peaks at 10 -l° mol/L and 10 -7 mol/L. A potent antagonist to ET B receptors, when used 
alone, had no effect. However, the antagonist, when combined with ET-1, significantly 
enhanced monocyte adherence to HUVECs. Incubation of ET-1 (10 -12 mol/L to 10 -7 
mol/L) with HUVECs activated tyrosine kinases in a biphasic manner as identified by 
immunoblotting with PY20 antibody to tyrosine phosphorylated proteins. Phosphory- 
lated proteins with Mr 60, 110, and 130 kDa were observed after ET-1 stimulation of 
HUVECs. Of interest, ET a or ET B receptor antagonists failed to antagonize the effect of 
ET-1. Rather, these receptor antagonists significantly augmented ET-1 induced tyrosine 
phosphorylation in HUVECs. Immunoprecipitation with antibodies to p60 src and JAK1 
kinases followed by immunoblotting with PY20 antibody suggested that ET-1 receptor- 
response coupling in HUVECs involves the activation of p60 src and JAKl-like kinases. 
Conclusions: These data suggest an association between activation of p60 src and JAKl-like 
kinases and monocyte adherence in response to ET- 1. ET- 1-induced monocyte adherence 
is upregulated by ETB receptor antagonist, suggesting a negative feedback on cell adhesion 
through this receptor. (J VAsc SURG 1996;23:288-300.) 
The initiating event in the pathogenesis o f  
atherosclerosis and intimal hyperplasia s endothelial 
damage. 1 Endothelial injury leads to a cascade of 
inflammatory events culminating in leukocyte adher- 
ence to the endothelium with concomitant release of 
mediators.~ Specific adhesive glycoproteins appear on 
the surface of the activated endothelial cells.1 These 
cell adhesion molecules include vascular cell adhe- 
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sion molecule-I, intercellular adhesion molecule-I, 
intercellular adhesion molecule-2, E-select_in, and 
P-selectin. 2,3 Interaction of selectins and members of 
the immunoglobulin superfamily with their ligands 
on leukocytes permits leukocyte adhesion to and 
subsequent migration through the endothelium un- 
der the influence ofchemoattractants, growth factors, 
and other chemicals released by the damaged endo- 
thelium, adherent leukocytes, and possibly smooth- 
muscle cells. 1'4 The exact molecular mechanisms 
involved are unknown but are likely to include 
upregulation of receptors uch as integrins on the 
leukocytes, upregulation of the expression of cell 
adhesion molecules on the endothelial cells, or both. 
Such upregulation of integrins or cell adhesion 
molecules could be due to increased transcription or 
increased translation of the proteins, which are 
enhanced by receptor-activated protein kinases and 
tyrosine kinases. 
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Fig. 1. EffectofET-1 (10-7mol/L) on monocyte adherence toHUVECs incubated with ET-1 
for various time periods. Percent increase above baseline monocyte adherence (in absence of 
ET-1) was calculated. Values are mean -+ SEM, n = 5-8. *p Value <0.05. 
Ischemia nd reperfusion are lmown to produce 
damage to endothelial cells and also to alter interac- 
tions between leukocytes and the endothellum. 3 
During ischemia nd reperfusion chemical mediators 
are released from activated leukocytes and the dam- 
aged endothelium. These mediators include super- 
oxide radicals, cytokines, growth factors, and other 
regulatory molecules. 5 Recently we reported an 
elevated level of endothelin-1 (ET-1) in serum after 
ischemia nd reperfusion. 6 ET-1 is a 21-amino acid 
polypeptide produced by vascular endothelial cells 
and is a potent modulator of vascular tone. 7 ET-1 has 
also been shown to enhance binding of leukocytes to 
human umbilical Vein endothelial cell (HUVEC) 
monolayers incubated with ET-1 for 2 to 24 hours 
(Edwards, McGregor, and Agrawal, unpublished 
observations). The effect of ET-1 on leukocyte 
adhesion to endothelial cells was similar to that of 
cytokines uch as interleuldn-1 and tumor necrosis 
factor-oc Because these factors play a pivotal role in 
the pathogenesis of several vascular diseases, the 
determination of the intracellular factors regulating 
leukocyte adherence to endothelium is paramount to 
expanding the understanding of the underlying 
mechanisms at the cellular and molecular level. 
We have recently reported that the tyrosine 
kinase inhibitors genistein and herbimycin A at- 
tenuate the adherence of leukocytes to cytokine- 
stimulated HUVECs. 8 In particular, monocyte ad- 
herence was completely attenuated. Because ET-1 
stimulated the adherence of monocytes to endo- 
thelial cells, we proposed the hypothesis that ET-1 
receptor activation of endothelial cells and the 
concomitant increase in cell adhesion involves ty- 
rosine kinase pathways, in particular tyrosine kinases 
of the Src and JAK families. This study investigates 
the underlying mechanisms involved in ET-1- 
induced adherence of monocytes to endothelial cells. 
MATERIAL AND METHODS 
Endothelial cell culture. Purified primary cul- 
tures (passage one) of HUVECs were obtained as 
cryopreserved cells from Clonetics Corp (San Diego, 
Calif.) and grown in endothelial cell growth medium 
(Clonetics) in culture flasks at 37 ° C under constant 
humidity in 5% CO2/95% air. s'9 The cells were 
isolated from normal human umbilical veins. All cells 
were tested for the presence of factor VIII-related 
antigen and for the uptake of the reagent Dil-Ac- 
LDL with immunofluorescent techniques, and all 
tested negative for human immunodeficiency virus 
and hepatitis B deoxyribonucleic a id. For adhesion 
studies HUVECs (passages 2 through 4) were grown 
to confluence in 96-well plates for a maximum of 48 
hours. 
Monocyte separation. Monocytes were isolated 
and purified with the methods established in our 
laboratories. 6's-1° In brief, on the morning of the 
experiment 120 ml of blood was collected from 
normal volunteers into heparinized tubes. Erythro- 
cytes were sedimented with 6% dextran-70 in 
normal saline solution. The leukocyte-rich layer was 
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harvested, washed with Hank's balanced salt solu- 
tion, and layered onto a discontinuous Percoll density 
gradient for centrifugation. The densities of Percoll 
used were 1.12, 1.090, 1.085, 1.080, and 1.077 
gm/ml. The monocytes and lymphocytes of the 
mononuclear layer were separated by plastic ad- 
herence. 
This procedure produces apurity of neutrophils 
more than 95%, monocytes more than 92%, and 
lymphocytes more than 90%. Cell viability was 
greater than 98% as determined by trypan blue dye 
exclusion. 
Monocyte adhesion studies. Isolated mono- 
cytes were radiolabeled with 51Cr-sodium chromate 
in the presence of 5% dextrose with continuous 
agitation. 8,9 Growth media in the 96-well plates were 
replaced with Roswell Park Memorial Institute 
(RPMI) 1640 medium without growth factors or 
fetal calf serum immediately before incubation of the 
HUVECs was performed with ET-1 for 4 hours at 
37 ° C in 95% air/5% CO 2 in the presence or absence 
of antagonist to ET B receptors. The wells were 
washed with RPMI 1640 medium, and then labeled 
monocytes were distributed over the wells (100,000 
monocytes per well) and incubated for 1 hour. The 
well plates were washed three times with RPMI 1640 
medium before adherent monocytes were har- 
vested from each well with a cotton tip applicator. 
The radioactivity was counted with a Beckman 
V-counter. 
Endothelial cell activation for immunoblot- 
ting. HUVECs (passages 2 through 4) were har- 
vested from culture, then suspended at106 cells/ml in 
RPMI 1640 medium without fetal calf serum or 
growth factors. Aliquots of cell suspension were 
incubated with ET-1 in the presence or absence of 
tyrosine kinase inhibitors, genistein (10-4 mol/L) or 
herbimycin A (8.75 × 10 -7 mol/L), or ET a or ET B 
receptor antagonist. Samples of HUVECs incubated 
with RPMI 1640 medium alone were run as control 
samples in each experiment. Reactions were stopped 
by centrifugation at 16,000g for 30 seconds. The 
pellets obtained were resuspended and homogenized 
in buffer (sucrose 250 mmol/L, Tris-HC110 mmol/L 
pH 7.5, ethyleneglycol tetraacetic acid 2 mmol/L, 
ethylenedimine tetraacetic acid 2 mmol/L, phenyl- 
methylsulphonyl fluoride 1 mmol/L) with 1% so- 
dium dodecylsulfate (SDS). An equal volume of 
Laemmli's buffer (final composition Tris-HC1 75 
mmol/L pH 6.8, SDS 2%, [~-mercaptoethanol 0.55 
mmol/L, bromophenol blue 0.003%, glycerol 
10%) H was added to each sample. The sample was 
boiled for 2 to 3 minutes and then centrifuged at 
3000g for 6 minutes before being stored frozen at 
-20  ° C for immunoblotting experiments. 
Agarose conjugation and immunoprecipita- 
tion. HUVECs were incubated with ET-1 or RPMI 
1640 medium (controls) as described previously. The 
pellets obtained on centrifugation were resuspended 
in immunoprecipitation assay buffer (phosphate- 
buffered saline solution with nonidet P-40 1%, 
sodium deoxycholate 0.5 %, SDS 0.1%, phenylmeth- 
ylsulphonyl f uoride 0.1 t~g/ml, sodium orthovana- 
date 1 mmol/L, aprotinin 30 ~l/ml) and then 
incubated with antibody to a specific tyrosine kinase. 
Where an agarose-conjugated primary antibody was 
available, the sample was incubated overnight with 
antibody at 4 ° C with continuous mixing. Where no 
agarose-conjugated primary antibody was available, 
the samples were first incubated with primary anti- 
body for 1 hour and then incubated overnight with 
primary antibody in the presence of protein A/G 
agarose. The cellular proteins conjugated to agarose 
were separated by centrifugation at 16,000g at 4 ° C 
for 20 minutes and washed several times, with 
immunoprecipitation assay buffer being collected by 
centrifugation after each wash. Finally, the pellets 
were suspended in 50 to 100 ~1 Laemmli's buffer in 
preparation for electrophoresis and immunoblotting. 
Western blotting. Aliquots of each sample were 
subjected to electrophoresis on 7.5% to 12.5% 
SDS-polyacrylamide g ls. In every gel a protein 
molecular weight marker was run alongside the 
samples being investigated. The proteins were trans- 
ferred onto nitrocellulose paper (0.2 ~zm, Schleicher 
and Schuell, Keene, N. H.) by electroblotting. 
overnight in a Biorad transblot electrophoretic cell at 
200 nzA. 
Nonspecific protein binding sites on the nitrocel- 
lulose membranes were blocked with 5% Carnation 
milk (Nestles Foods; Glendale, Calif.). The mem- 
branes were washed before incubation with primary 
antibody at 1:1000 dilution for 2 hours and then 
with secondary antibody conjugated to horseradish 
peroxidase (1:5000 dilution for 1 hour). Protein 
bands were detected with enhanced chemilumines- 
cence reagent followed by exposure of the blot to 
autoradiography film. 
Tyrosine kinase inhibitors and endothelin re- 
ceptor antagonists. Genistein 10 4 mol/L (Sigma 
Chemical Co., St. Louis, Mo.) and 8.75 × 10 -7 
mol/L herbimycin A (Calbiochem, La Jolla, Calif.) 
were the ryrosine kinase inhibitors used; the concen- 
trations chosen were those at which inhibition of 
tyrosine kinases is selective and complete without 
affecting other kinases.12,13 
JOURNAL OF VASCULAR SURGERY 
Vohune 23, Number 2 Chishollc4 et al. 291 
In the adhesion studies the selective antagonist 
to ET B receptors (Cysn-CyslS)-ET-l(11-21) was 
used. 14 For immunoblotting the linear tripeptide 
derivative BQ-610 was used as antagonist to ET A 
receptors. I  A related compound, BQ-788, was used 
in addition to (Cysll-CyslS)-ET-l(ll-21) as an- 
tagonist o ET B receptors. 16a7 All the antagonists 
are potent and selective for their respective 
receptorsJ 4q6 
Antibodies. PY20, a mouse monoclonal immu- 
noglobulin 2a antibody reactive against phospho- 
tyrosine-containing proteins, was used in the immu- 
noblotting studies. 
C-src, a rabbit polyclonal antibody raised against 
a peptide corresponding to residues 509 to 533 
within the carboxy-terminal region of the human src 
gene product, reacts with p60 src, p62 yeS, and p59 fyn of 
human, mouse, and rat origin. It does not cross-react 
with other src gene family tyrosine kinasesJ 7
The agarose-conjugate d anti-c-src antibody is an 
affinity-purified polyclonal rabbit antibody raised 
against a peptide corresponding to residues 3 to 18 
within the amino-terminal region of the human src 
gene product. It reacts with p60 src only. No cross- 
reactivity with other members of the Src gene family 
is detectable. 
JAK1 and JAK2 are rabbit polyclonal antibodies 
raised against peptides corresponding to amino acids 
785 to 804 and 758 to 776, respectively, which map 
within the hinge region between domains 1and 2 of 
mouse JAK1 and JAK2. The antibodies are specific 
for JAK1 or JAK2, respectively, of human, mouse, 
and rat origin. Neither antibody cross-reacts with the 
other, nor do they cross-react with tyk2. 
A control peptide in the form of a polypeptide 
comprising the amino acid sequence against which 
the antibody was raised was run in parallel with 
each experiment to determine nonspecific antibody 
binding. 
Reagents.  General chemical reagents were ob- 
tained from Sigma Chemical Co. (St. Louis) and 
Fisher Scientific (St. Louis). ET-1 and (Cysn-CyslS) - 
ET-1(11-21) were obtained from BACHEM Corp. 
(Torrance, Calif.). The antagonist to ET A receptors 
(BQ610) and the antagonist o ET B receptors 
(BQ788) were purchased from Peptides Interna- 
tional (Louisville, Ky.). Genistein and herbimycin A, 
the tyrosine kinase inhibitors, were suppfied by 
Sigma Chemical Co. and Calbiochem, respectively. 
All antibodies were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, Calif.). Enhanced 
chemiluminescence reagent and 14C-labeled rainbow 
protein molecular weight markers were purchased 
from Amersham (Arlington Heights, Ill.). SlCr- 
sodium chromate was purchased from DuPont 
New England Nuclear (Cambridge, Mass.). Nitro- 
cellulose paper, pore size 0.2 Ixm, was obtained from 
Schleicher and Schuell. Kodak X-omat autoradiog- 
raphy film (Eastman Kodak; Rochester, N.Y.) was 
used to detect chemiluminescence. 
RESULTS 
Monocyte Adhesion to HUVEC Monolayers 
ET-1 enhanced the adhesion of monocytes to 
HUVECs with a maximum increase at 4 hours 
(p < 0.05) (Fig. 1). Adhesion of monocytes to 
endothelial cells was enhanced atall the doses ofET-1 
used (10 -14 mol/L to 10 -7 tool/L). ET-1 had a 
biphasic effect with peaks in monocyte adherence at
10 -12 mol/L and 10 -7 mol/L (Fig. 2). Phosphora- 
midon (10 -5 tool/L), a metalloprotease inhibitor 
that inhibits the processing of big ET-1 into the 
biologically active form ET-1,18 had no effect on 
adherence when used with ET-1 (Fig. 3). However, 
when the endothelial cells were incubated with 
genistein or herbimycin A for 15 minutes before 
ET-1 was added (10 -8 mol/L or 10 -11 tool/L), 
attenuation of ET-1-induced adherence to endothe- 
lial cells (Fig. 4) occurred. Genistein completely 
inhibited 10 -11 mol/L ET-1 induced monocyte 
adhesion (Fig. 4). 
To examine the specificity of the effect of ET-1, 
HUVECs were incubated with ET B receptor antago- 
nist (Cys n to CyslS)-ET-l(11-21) (10 -s tool/L) for 
15 minutes before ET-1 was added. Exposure of 
HUVECs to ET B receptor antagonist before incu- 
bation with ET-1 significantly enhanced by two- to 
fourfold the adherence ofmonocytes tothe HUVEC 
monolayers (Fig. 5). Endothelin-B receptor antago- 
nist alone had no effect. 
Immunoblotting 
Time course. To demonstrate he increased ac- 
tivity of tyrosine kinases in response to ET-1 in 
HUVECs, cells were incubated with ET-1. The 
optimum incubation period was determined by 
incubating HUVECs with a single physiological dose 
of ET-1 (10 -8 mol/L) for various time periods 
ranging from 30 seconds to 30 minutes. In the 
immunoblotting experiments with PY20 antibody, 
several proteins with molecular weights ranging from 
Mr 30 to 130 kDa were noted; the strongest ignal 
came from bands of molecular weight Mr 110 to 130 
kDa and 60 kDa (Fig. 6). ET-l-dependent tyrosine 
phosphorylation f proteins in HUVECs was clearly 
evident with incubation periods as short as 30 
seconds (Fig. 6). Maximum phosphorylation oc- 
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Fig. 2. Dose response ffect of ET-1 on monocyte adherence to HUVECs. Monocytes were 
incubated with various doses of ET-1 for 4 hours under defined experimental conditions. Values 
are mean + SEM, n = 7. 
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Fig. 3. Effect of phosphoramidon (10 -5 tool/L) on ET-l-induced monocyte adherence to 
HUVECs. HUVECs were preincubated with phosphoramidon for 15 minutes before 
incubation with ET-1 10 -8 mol/L or ET-1 10 -11 mol/L for 4 hours. Values are mean _+ SEM, 
n=4.  
curred at 3 minutes and then greatly diminished after 
5 minutes. It is interesting that at 30 minutes tyrosine 
phosphorylated proteins reappeared. 
Dose response curve. To determine a concen- 
tration/response r lationship for ET-1, HUVECs 
were incubated with ET-1 at doses from 10-7 mol/L 
to 10 -13 mol/L for 3 to 5 minutes. The response to 
ET-1, as measured by the intensity of  the tyrosine 
phosphorylated proteins, was biphasic, with peaks at 
10 7 mol/L and 10 -12 mol/L for the bands of Mr 
110 to 130 kDa (Fig. 7). However, the effect of ET-1 
on the protein of Mr 60 kDa was not biphasic. 
Maximum expression of this protein occurred at 10- 8 
mol/g.  
Effect o f  tyrosine ldnase inhibitors. To inves- 
tigate the effect of the selective tyrosine kinase 
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Fig. 4. Effect oftyrosine kinase inhibitors on ET-l-induced monocyte adherence toHUVECs. 
HUVECs were incubated with genistein (G) 10 -4 mol/L or herbimycin A (H) 8.75 × 10 -7 
mol/L for 15 minutes before addition of ET- 1 10- 8 mol/L or ET- 1 10-11 mol/L. HUVECs were 
then incubated for 4 hours at 37 ° C in 95% air/5% CO 2 in humidified chamber. Values are 
mean +- SEM, n = 6-8. *p < 0.05; **p < 0.01. 
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Fig. 5. Effect of ET-1 in presence and absence ofendothelin-B receptor antagonist IRL 1038 
(10 -s mol/L) on monocyte adherence to HUVECs. HUVECs were incubated with ET B 
receptor antagonist for 15 minutes before incubation with ET-1 at various doses. Values are 
mean +__ SEM, n = 7. 
inhibitors genistein and herbimycin A, HUVECs  
were incubated with one inhibitor for 10 minutes 
before being incubated with ET-1 (10 :  s mol /L  and 
10 - l °  tool/L) for 3 minutes. Both tyrosine kinase 
inhibitors attenuated the signal detected by PY20 
ant ibody at all molecular weights including Mr  110 
to 130 kDa. The attenuation o f  the 60 kDa band was 
marked at ET-1 10 -1° mol /L  but  was less marked 
when ET-1 10 -s  mo l /L  was used (Figs. 6 and 7). 
Ef fect  o f  ET  A and  ET  B receptor  antagonis ts .  
To determine whether the effect o f  ET-1 involved 
activation o f  ET A or ET B receptors, the effect o f  
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Fig. 6. Time course for effect of ET-1 (10 _8 mol/L) on production oftyrosine phosphorylated 
proteins by HUVECs as detected by immunoblotting with PY20. Lanes marked G and H are 
samples where HUVECs were incubated with tyrosine kinase inhibitor genistein ((7) 10 -4 
mol/L or herbimycin A (H) 8.75 x 10 -7 mol/L for 10 minutes before addition of ET-1 10 -8 
mol/L for 5 minutes. Data rerepresentative of three experiments. 
antagonists to ET A and ETB receptors was also 
investigated. HUVECs were incubated with an 
antagonist to ETA or ET• receptors for 10 minutes 
before being incubated with ET-1 (10 7 mol/L). 
Each antagonist markedly enhanced the ET-1- 
induced expression of tyrosine phosphorylated pro- 
teins as recognized by PY20 antibody, particularly at 
Mr 60 and 110 to 130 kDa (Fig. 8). However, the 
enhancement was not prominent with antagonist 
alone. 
Immunoblotting with antibodies to specific 
tyrosine ldnases. To determine whether HUVECs 
contain tyrosine kinases, antibodies against he spe- 
cific tyrosine kinases c-src, JAK1, and JAK2 were 
used to immunoblot cell lysates obtained from 
HUVECs. Each sample was also immunoblotted 
with the appropriate control pcptide. C-src antibody 
reacted with several protein bands of Mr 38 to 110 
kDa in both control HUVECs and those stimulated 
with ET-1. The strongest signal came from proteins 
with molecular weights of approximately 60 kDa 
(Fig. 9). 
Antibody to JAK2 dctectcd three protein bands 
of Mr 110 to 130 kDa and a Mr 55 kDa band. The 
control peptide recognized the Mr 55 kDa band. 
IAK1 antibody detected three protein bands of Mr 
58, 60, and 90 kDa (Fig. 9). The control peptide 
detected a very faint band of Mr 58 kDa, which could 
have been due to the use of excess control peptide 
demonstrating nonspecific binding of the antibody. 
Immunoprecipitation and Western blotting. 
To demonstrate he involvement and activation ofsrc 
kinases in response toET-1, HUVECs (7 x 106 cells 
in 1 ml) were incubated with ET-1 (10 -8 mol/L or 
10-12 mol/L) for 3 minutes. The solublized proteins 
from these HUVECs were immunoprecipitated 
with agarose-conjugated antibody to p60 src. The 
immunoprecipitated c-src reactive proteins were 
immunoblotted with PY20 antibody to tyrosine 
phosphorylated proteins and with antibody to c-src. 
Endothelin-1 dependent tyrosine phosphorylation 
of proteins with molecular weights of Mr 52, 60, 
and 62 kDa, appropriate for src, were clearly evident 
in lysates from HUVECs incubated with ET-1 for 
3 minutes at physiological concentrations of ET-1 
as low as 10 -12 mol/L (Fig. 10). Tyrosine phos- 
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phorylated proteins of Mr 32, 38, and 190 kDa 
were also evident in cell lysates from HUVECs 
incubated with ET-1. As a control sample, the 
immunoprecipitated c-src reactive proteins were 
immunoblotted with e-src. The detected proteins 
were similar in samples from both stimulated and 
unstimulated HUVECs (Fig. 10). 
Cell lysates from control HUVECs and HU- 
VECs incubated with ET-I were also immunopre- 
cipitated with antibody to JAK1 conjugated to agar- 
ose. Immunoblotting of these immunoprecipitates 
with PY20 demonstrated ET-l-dependent tyrosine 
phosphorylation f proteins of Mr 65 and 72 kDa. 
The immunoprecipitates were blotted with antibody 
to JAK1 as a control sample, demonstrating tyrosine 
phosphorylated proteins in samples from both stimu- 
lated and unstimulated HUVECs (Fig. 11). 
In the initial experiments after immunoprecipita- 
tion was performed, the supematants were collected 
and run on gels in the usual manner. No proteins of 
interest were detected on immunoblotting with the 
antibodies used. 
DISCUSSION 
In studies related to cancer cell lines, investiga- 
tions have found that excessive signaling by receptor 
tyrosine kinases results in inappropriate cell prolif- 
eration. We hypothesize that the regulation of 
intimal repair after vascular injury may also be subject 
to such tyrosine kinase-dependent mechanisms, with 
the potential for excessive proliferation and intimal 
hyperplasia. Cytokines and growth factors regulate 
cellular proliferation and differentiation by inducing 
tyrosine kinases, which may be either part of a 
receptor or cytoplasmic tyrosine kinases constitu- 
tively activated by a receptor. Tyrosine kinases 
phosphorylate tyrosine moieties on receptors or 
kinase substrates recruited by receptor activation. 
The phosphorylated protein in turn may activate one 
or more transcriptional factors to induce transcrip- 
tion of receptor-stimulated genes. In recent years 
much research has focused on this area. Interleukin-1 
and rumor necrosis factor-a are known to enhance 
leukocyte-endothelial cell interaction. However, the 
underlying mechanisms are unknown. 
In this study we observed that the regulatory 
peptide hormone ET-1 increased the adherence of 
monocytes to endothelial cells in culture. The in- 
creased adherence produced by ET-1 was attenuated 
by the selective tyrosine kinase inhibitors, genistein 
and herbirnycin A. The doses of genistein and 
herbimycin A used are specific for tyrosine kinases 
and do not inhibit protein kinase C or protein kinase 
Fig. 7. Dose response effect of ET-1 on production of 
tyrosine phosphorylated proteins by HUVECs as detected 
by immunoblotting with PY20. Lanes marked G andH are 
samples of HUVECs incubated with tyrosine kinase 
inhibitors genistein (G) l0 -4 mol/L or herbimycin A (H) 
8.75 x 10 -7 mol/L for 10 minutes before addition of 
ET-1 10 ~0 mol/L for 5 minutes. Data are representative of 
two individual experiments. 
A. This finding clearly suggests the involvement of 
tyrosine kinases in ET-1 induced adhesion of mono- 
cytes to endothelial cells. This involvement is con- 
firmed by the appearance oftyrosine phosphorylated 
proteins in HUVECs after incubation with ET-1 in 
physiological doses. The time course study revealed 
that phosphorylation was rapid and transient. An- 
tiphosphotyrosine antibody, PY20, recognized a 
number of tyrosine phosphorylated proteins in 
HUVECs, particularly of Mr 60, 72, 110, and 130 
kDa. 
Some variability exists in the relative magnitude 
of phosphorylation f these substrates after stimula- 
tion with ET-1 (Figs. 6 and 7). This variability could 
be related to the experimental variation in the age of 
HUVECs (passage 2 vs passage 3 or 4),reagents used 
in the study, or both. 
In several cell systems ET-1 has been reported to 
activate phospholipase C by a pertussis toxin-sen- 
sitive G-protein) 9 Phospholipase C stimulates the 
second messengers of the phosphoinositol cascade, 
which elevate intracellular calcium and activate pro- 
tein kinase C. Phospholipase A 2 is also activated, 
resulting in release of arachidonic acid. z° In intact 
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Fig. 8. Effect of ET A and ET B receptor antagonists on tyrosine phosphorylated proteins as 
detected by immunoblotting with PY20. HUVECs were incubated with ET A receptor 
(5 x 10 -8 mol/L) and ETB receptor antagonist (5 x 10 -7 tool/L) for 10 minutes alone or 
before addition of ET-1 10-s mol/L for 5 minutes of incubation. Lane marked G shows effect 
of incubating HUVECs with genistein (G) 10 -4 mol/L for 10 minutes before addition of ET-1 
10 -8 mol/L for 5 minutes. 
Fig. 9. Immunoblotting of ET-I-(10 -s mol/L) stimulated HUVECs with antibody to src, 
JAK1, or JAK2 or appropriate control peptide (CP). This is representative of four separate 
experiments. 
blood vessels ET-1 stimulation increases phospholi- 
pase D activity? 1 Endothelin-1 also alters the cell 
membrane potential, probably by a mechanism 
involving both ligand and voltage gated calcium 
channels. 22 In our study we observed that ET-1 
activated tyrosine kinases in HUVECs. This finding 
suggests that the ET- 1 receptor, which belongs to the 
family of receptors with seven transmembrane do- 
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Fig. 10. Immunoprecipitation of ET-I-stimulated and control HWECs with antibody to 
p60 ~rc followed by immunoblotting with PY20 or antibody to c-src. This is representative of 
three separate experiments. 
mains ,  23,24 is coupled to multiple signaling pathways. 
However, it is not clear whether these pathways are 
activated independently or in parallel, or whether the 
activation of tyrosine ldnases and the resulting 
tyrosine phosphorylated proteins can activate a 
G-protein, which then activates phospholipase C. 
The activation of protein kinase C may occur as a 
consequence of activation of a phospholipase by 
tyrosine phosphorylation. Such a mechanism has 
been reported in T-cell receptor stimulation. 2527 
Immunoprecipitation with specific antibodies to 
src kinases followed by immunoblotting with PY20 
demonstrated the activation of p60 src kinase in 
ET-l-stimulated HUVECs. In addition to the 60 
kDa protein, tyrosine phosphorylated proteins with 
Mr 32, 38, 62, and 190 kDa were consistently 
observed after ET-1 stimulation. The proteins of Mr 
62 and 190 kDa could be related to glutamyl 
transpeptidase-activating protein. Tyrosine kinases 
have been reported to induce glutamyl transpep- 
tidase-activating protein to complex with Mr p62 and 
p190 kDa tyrosine phosphorylated proteins. 28 It has 
been speculated that the p62 and p190 kDa proteins 
might regulate or be the target of various oncogene 
products such as ras. 29 Further experiments are 
warranted to confirm the nature of the p62 and p190 
proteins. The p32 and p38 proteins could be the 
breakdown products of a larger protein or novel 
tyrosine phosphorylated proteins formed in ET-1 
stimulated endothelial cells. The degradation of a 
larger protein is highly unlikely, because the experi- 
ments were carried out in the presence of protease 
inhibitors. Nevertheless activation of HUVECs by 
ET-1 consistently caused the appearance of several 
tyrosine phosphorylated proteins, which were recog- 
nized by anti-src antibody. 
In addition to the activation of src kinases, ET-1 
appeared to activate IAK-like kinases. JAK ldnases 
are present in HUVECs (Fig. 9). Kinases of the Janus 
family such as JAK1 are important in signal trans- 
duction by interferons. 3° In our study JAK1 antibody 
detected three proteins at Mr 58, 60, and 90 kDa. 
The molecular weight of Janus kinases is 130 kDa, 31 
and in other cell lines the JAK1 antibody detected a 
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Fig. 11. Immunoprecipitation of ET-l-stimulated and 
control HUVECs with antibody to JAK1 followed by 
immunoblotting with PY20 or antibody to JAK1. This is 
representative of three separate experiments. 
130 kDa protein. Because specific antibody to JAK1 
ldnases consistently recognized Mr 58, 60, and 90 
kDa proteins, we speculate hat hese proteins possess 
some antigenic resemblance to JAK1 kinases. There- 
fore we call the kinases involved in HUVECs 
"JAKl-like kinases." Nevertheless immunoprecipita- 
tion with IAKI antibody followed by immunoblot- 
ting with antibody to tyrosine phosphorylated pro- 
teins demonstrated activation of proteins with mo- 
lecular weight 65 and 72 kDa in ET-1 stimulated 
HUVECs. This finding clearly suggests he activation 
of one or more kinase and that the phosphorylated 
products of these kinases are recognized by the JAK1 
antibody used in this study. Further elucidation of 
the nature of these proteins i  required. IAI(2 kinases, 
with a molecular weight of 130 kDa, are present in 
the endothelial cells. However, in our preliminary 
experiments we did not observe any tyrosine phos- 
phorylated proteins related to IAK2 after ET-1 
stimulation of HUVECs (data not shown). 
Thus ET-i activation of endothelial cells activates 
p60 src and JAKl-like kinases. The exact mechanism 
by which ET-1 activates these kinases is not clear. 
Furthermore, how the tyrosine phosphorylated pro- 
teins activate transcriptional f ctors and regulate gene 
transcription for cell adhesion molecules has yet to be 
examined. Tyrosine ldnase-dependent pathways have 
been implicated in cytokine-initiated intracellular 
signaling and upregulation of endothelial cell adhe- 
sion molecules, including those affecting monocyte 
adherence to endothelial cells. 32 In cells such as 
lymphocytes and fibroblasts, receptor-ligand binding 
produces an interaction between cytokine receptor 
chains and protein tyr0sine kinases, resulting in 
Ph0sphorylation of the tyrosine kinasesY -34 This 
interaction permits interaction between the tyrosine 
kinases and a transcriptional f ctor such as a member 
of the signal transducer and activator of transcription 
family. A tyrosine moiety on the transcriptional 
factor is then phosphorylated, and protein dimers are 
formed. 31,32 The dimers translocate into the nucleus, 
where they interact with deoxyribonucleic a id to 
direct ranscription. Thus binding of a cytokine to its 
receptor can initiate the production of specific 
proteins. Such a mechanism ay be involved in the 
interaction of ET-1 with its receptor on the endo- 
thelial cell, the transcriptional f ctor ultimately initi- 
ating production of proteins including cell adhesion 
molecules. In our adherence studies we have shown 
that ET enhanced monocyte adherence toendothelial 
cells at 2 to 4 hours. Such a time period is sufficient 
to attribute this enhancement to increased messenger 
ribonucleic acid synthesis and translation of that 
messenger ribonucleic acid into cell adhesion mol- 
ecule proteins on the endothelial cell surface. There- 
fore it is likely that the activation of ET receptors 
increases transcription and translation of cell adhe- 
sion molecules via tyrosine kinase signal transduction 
pathways. 
Endothelial receptors comprise two distinct 
types. These are ET B receptors, which are promincnt 
on endothelial cells, and ET A receptors, which are 
found on vascular smooth-muscle ells.35 Because n- 
dothelial cells are rich in ET B receptors, ET B receptor 
antagonist was expected to block the ET-l-induced 
increase in monocyte adherence toHUVECs. How- 
ever, ET B receptor antagonist produced a two- to 
fourfold increase in adherence compared with ET-1 
alone. This increase may have been the result of a 
partial agonist effect of the ETa receptor antagonist 
used. However, ET B receptor antagonist alone did 
not alter monocyte adherence ofthe HUVEC mono- 
layers. In addition, in our preliminary studies ET A 
receptor antagonist also potentiated ET-1 (10-11)_ 
induced monocyte adherence to endothelial cells. A 
similar effect was observed when control and ET-1 
stimulated HUVECs were incubated with antagonist 
to either ET A of ET B receptors. Imnmnoblotting to 
detect tyrosine phosphorylated proteins in HUVECs 
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demonstrated marked enhancement of the effect of 
ET-1 on tyrosine phosphorylation. Again, both an- 
tagonists markedly augmented the effect of ET-1 on 
tyrosine phosphorylation in HUVECs. These data 
suggest hat ET-1 induced monocyte adherence is 
mediated by a novel ET-1 receptor that is under the 
negative regulatory control of ET A and ET B recep- 
tors on endothelial cells. Whether such a negative 
feedback loop exists as a natural defense mechanism is 
as yet unknown. However, in a pathologic ondition 
the role of such a mechanism cannot be ruled out. 
In summary, the experiments presented in this 
article suggest hat novel ET-1 receptors are present 
on endothelial cells and that activation of these 
receptors by ET-1 activates p60 src and JAKl-like 
kinases. To our knowledge this is the first report 
of the involvement of tyrosine kinase pathways in 
response to ET-1 receptor interaction. The rela- 
tionship of tyrosine phosphorylation and the in- 
creased expression of cell adhesion molecules re- 
mains to be defined. The elucidation and charac- 
terization of the intracellular molecules may 
facilitate the development of pharmacologic or im- 
munologic tools to prevent or ameliorate hyper- 
plasia and atherosclerosis. 
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